Funding Details
- Awarder
- RSS - feed.businesswire.com
- Date Award
- August 07, 2024
- Vertical
- Biopharmaceuticals
- Funding URL
- View Funding Page
- Funding Amount:
-
$120,000,000
Company Info
- Founding Year
- 2021
- Traction
- IDRx is currently enrolling patients in the Phase 1b portion of the StrateGIST 1 trial, which has shown promising preliminary Phase 1 data.
- Organizations Involved
- U.S. Food and Drug Administration (FDA), American Society of Clinical Oncology (ASCO)
- Founders
- Nick Lydon, Ph.D.
- Company Description
- Idrx is a clinical-stage biopharmaceutical that develops oncology-based precision therapies to treat cancer.
- Market
- Cancer Treatment
- Location
-
Plymouth,
Massachusetts,
US
- Coinvestors
- RA Capital Management, Commodore Capital, Blackstone Multi-Asset Investing, Rock Springs Capital, Merck KGaA, Andreessen Horowitz, Casdin Capital, Nextech Invest Ltd., Forge Life Science Partners
Links